Merck's eye disease drug meets main goal in trial
MRK•Merck said its drug met the main goal in a mid- to late-stage trial in adults with a disease affecting blood vessels at the back of the eye.
1. Trial result
Merck said its drug met the main goal in a mid- to late-stage trial testing it in adults with a type of disease that affects blood vessels at the back of the eye.
